Loading…
Loading…
Pilot
Hospital buyers love low-risk entry points. This pilot is time-boxed, narrowly scoped, KPI-driven, low-lift, priced to signal seriousness, and trivially convertible to enterprise — with the success threshold defined before day one.
The ARKA Standard — the published constraints this pilot is held to.
ARKA helps organisations carrying total cost of care turn low-value imaging into attributable shared savings — a risk-adjusted peer comparison ledger for attributed lives, with no EHR integration for the first product — ~$1M avoidable per 100,000 lives modelled, of which 50–75% is retained under ACO Shared Savings Program tracks.
There are no FHIR scopes, because there is no integration.
Virtual-first providers. For a virtual-first organisation with no scanners, no RIS, and no imaging service line to defend, deployment is the shortest path ARKA has: register CDS Hooks on the encounter surface you already run, name a clinical owner, and measure ordering against a locked pre-period — there is no protocoling problem, no capital equipment, and no imaging revenue to protect. The entire clinical interaction is the telehealth or virtual visit ARKA already sits in.
30–90 days
One service line or one payer — e.g., outpatient MRI/CT for one commercial plan
Fixed pilot fee — credited toward enterprise
Priced to signal seriousness, not to profit. See pricing tiers
Pilot → enterprise: same integration, widen scope; no re-implementation.
Success contract
These metrics are your signed scorecard — baseline, target, and how each is measured. For the full outcomes framework across revenue, efficiency, clinical adoption, and compliance, see outcomes & KPIs.
| KPI | Baseline | Target | How measured |
|---|---|---|---|
| First-pass clean-claim rate | Typical 75–85% on advanced imaging (your rev-cycle baseline) | Material improvement on the scoped cohort vs. baseline | Rev-cycle denial extracts + ARKA validation cohort; weekly pilot readout |
| Advanced-imaging denial rate | 20–40% initial denial on high-cost imaging (industry band) | Material reduction on scoped service line / payer | ROI dashboard denial trend for pilot cohort |
| Auto-clear rate (orders never queued) | 0% without in-flow appropriateness + payer-side check | 35–40% of clearly appropriate orders auto-cleared | INS reviewer queue + validation dashboard auto-clear metrics |
| Prior-auth turnaround time | Manual queue; often beyond CMS-0057-F standard / expedited SLAs | Within simulated CMS-0057-F decision windows (72h expedited / 7 calendar days standard) | Reviewer queue SLA timers + PAS endpoint conformance checks |
| Clinician clicks added | N/A — baseline is zero added workflow | 0 — silent unless a guideline fires | CDS Hooks card delivery logs; champion sign-off during shadow mode |
The pilot instrument is also the research instrument.
Defined jointly up front; if the pilot misses it, month 1 of production is free (existing guarantee).
What happens after day 90? Monthly ops reviews, quarterly business reviews, and shared accountability through production scale — see how success is governed after go-live.
Low risk
Each criterion hospital procurement teams ask for — explicitly met by this offer.
Time-boxed — met
30–90 days with weekly readouts and a fixed end date — not an open-ended evaluation.
Narrowly scoped — met
One department, one payer, or one population — e.g., outpatient MRI/CT for a single commercial plan.
KPI-driven — met
Success metrics co-written before kickoff; the table below is your signed scorecard.
Low-lift — met
Standard CDS Hooks / SMART on FHIR registration — one EHR analyst, light ARKA support; no custom interface engine.
Convertible — met
Same integration widens to enterprise scope — no rip-and-replace when you scale systemwide.
Next step
We co-write the success threshold, align on Phase 0–1 entry criteria, and keep the same integration when you widen to enterprise. Phase 0 paperwork starts on the ARKA Vendor Portal.
ARKA is Non-Device Clinical Decision Support under FD&C Act §520(o)(1)(E). The ordering clinician retains full responsibility for the final decision. Regulatory rationale.
Pilot
Hospital buyers love low-risk entry points. This pilot is time-boxed, narrowly scoped, KPI-driven, low-lift, priced to signal seriousness, and trivially convertible to enterprise — with the success threshold defined before day one.
The ARKA Standard — the published constraints this pilot is held to.
ARKA helps organisations carrying total cost of care turn low-value imaging into attributable shared savings — a risk-adjusted peer comparison ledger for attributed lives, with no EHR integration for the first product — ~$1M avoidable per 100,000 lives modelled, of which 50–75% is retained under ACO Shared Savings Program tracks.
There are no FHIR scopes, because there is no integration.
Virtual-first providers. For a virtual-first organisation with no scanners, no RIS, and no imaging service line to defend, deployment is the shortest path ARKA has: register CDS Hooks on the encounter surface you already run, name a clinical owner, and measure ordering against a locked pre-period — there is no protocoling problem, no capital equipment, and no imaging revenue to protect. The entire clinical interaction is the telehealth or virtual visit ARKA already sits in.
30–90 days
One service line or one payer — e.g., outpatient MRI/CT for one commercial plan
Fixed pilot fee — credited toward enterprise
Priced to signal seriousness, not to profit. See pricing tiers
Pilot → enterprise: same integration, widen scope; no re-implementation.
Success contract
These metrics are your signed scorecard — baseline, target, and how each is measured. For the full outcomes framework across revenue, efficiency, clinical adoption, and compliance, see outcomes & KPIs.
| KPI | Baseline | Target | How measured |
|---|---|---|---|
| First-pass clean-claim rate | Typical 75–85% on advanced imaging (your rev-cycle baseline) | Material improvement on the scoped cohort vs. baseline | Rev-cycle denial extracts + ARKA validation cohort; weekly pilot readout |
| Advanced-imaging denial rate | 20–40% initial denial on high-cost imaging (industry band) | Material reduction on scoped service line / payer | ROI dashboard denial trend for pilot cohort |
| Auto-clear rate (orders never queued) | 0% without in-flow appropriateness + payer-side check | 35–40% of clearly appropriate orders auto-cleared | INS reviewer queue + validation dashboard auto-clear metrics |
| Prior-auth turnaround time | Manual queue; often beyond CMS-0057-F standard / expedited SLAs | Within simulated CMS-0057-F decision windows (72h expedited / 7 calendar days standard) | Reviewer queue SLA timers + PAS endpoint conformance checks |
| Clinician clicks added | N/A — baseline is zero added workflow | 0 — silent unless a guideline fires | CDS Hooks card delivery logs; champion sign-off during shadow mode |
The pilot instrument is also the research instrument.
Defined jointly up front; if the pilot misses it, month 1 of production is free (existing guarantee).
What happens after day 90? Monthly ops reviews, quarterly business reviews, and shared accountability through production scale — see how success is governed after go-live.
Low risk
Each criterion hospital procurement teams ask for — explicitly met by this offer.
Time-boxed — met
30–90 days with weekly readouts and a fixed end date — not an open-ended evaluation.
Narrowly scoped — met
One department, one payer, or one population — e.g., outpatient MRI/CT for a single commercial plan.
KPI-driven — met
Success metrics co-written before kickoff; the table below is your signed scorecard.
Low-lift — met
Standard CDS Hooks / SMART on FHIR registration — one EHR analyst, light ARKA support; no custom interface engine.
Convertible — met
Same integration widens to enterprise scope — no rip-and-replace when you scale systemwide.
Next step
We co-write the success threshold, align on Phase 0–1 entry criteria, and keep the same integration when you widen to enterprise. Phase 0 paperwork starts on the ARKA Vendor Portal.
ARKA is Non-Device Clinical Decision Support under FD&C Act §520(o)(1)(E). The ordering clinician retains full responsibility for the final decision. Regulatory rationale.